SCTX (Scribe Therapeutics) Research & Development: $11.31 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCTX Scribe Therapeutics Inc SCTX
8 GF Score
Price $22.00
View Full Analysis

What is Scribe Therapeutics Research & Development?

Scribe Therapeutics SCTX -13.40% 8 Research & Development is $11.31 Mil as of Mar. 2026. GuruFocus rates SCTX with a GF Score™ of 8/100.

Research & Development is the aggregate amount of research and development expenses during the year. Scribe Therapeutics's Research & Development for the three months ended in Mar. 2026 was $11.31 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $11.31 Mil.

Scribe Therapeutics  (NAS:SCTX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Scribe Therapeutics Research & Development Related Terms

Scribe Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Scribe Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scribe Therapeutics Research & Development Chart

Scribe Therapeutics Annual Data
Trend Dec24 Dec25
Research & Development
57.08 60.80

Scribe Therapeutics Quarterly Data
Dec24 Mar25 Dec25 Mar26
Research & Development 0.00 15.99 0.00 11.31
SCTX
8GF Score
Scribe Therapeutics Inc SCTX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scribe Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $11.31 Mil mean?
Scribe Therapeutics (SCTX) has a Research & Development of $11.31 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Scribe Therapeutics and its competitors.
Is Scribe Therapeutics' Research & Development too high?
Scribe Therapeutics' current Research & Development is $11.31 Mil. Overall, Scribe Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Scribe Therapeutics' Research & Development compare to ?
Scribe Therapeutics' Research & Development of $11.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Scribe Therapeutics and its competitors. Scribe Therapeutics's current Research & Development is $11.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scribe Therapeutics stock overvalued right now?
Scribe Therapeutics (SCTX) has a current Research & Development of $11.31 Mil. The current Research & Development is $11.31 Mil. Scribe Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Scribe Therapeutics (SCTX), the current Research & Development is $11.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scribe Therapeutics Business Description

Comparable Companies
Address 1150 Marina Village Parkway, Alameda, CA, USA, 94501
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
8GF Score

Get the complete analysis for SCTX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.00
Price